Clinical Trials In Chicago

Discover hundreds of clinical trials in Chicago.
Search clinical trials in Chicago by condition or phase.

e.g. Respiratory Diseases

Chicago•Healthy volunteers: No

Filter results

Results: 2,251

Longitudinal Study of the Porphyrias

Recruiting

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Chicago, Birmingham, Los Angeles, San Franciscoshow 11 more

Code:

NCT01561157

Conditions

Acute Porphyrias

Cutaneous Porphyrias

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

Recruiting

Sponsor:

Northwestern University

Location:

Chicago

Code:

NCT01531257

Conditions

Acute Rejection (AR) of Transplanted Kidney

Chronic Allograft Nephropathy (CAN)

Interstitial Fibrosis (IF)

Tubular Atrophy (TA)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Recruiting

Phase 3

Sponsor:

Dermavant Sciences, Inc.

Location:

Chicago, Rogers, Fountain Valley, Rancho Santa Margaritashow 7 more

Code:

NCT05172726

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

tapinarof cream, 1%

Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder

Recruiting

Phase 3

Sponsor:

Neumora Therapeutics, Inc.

Location:

Chicago, Warrenville, Evanston, Huntsvilleshow 55 more

Code:

NCT06029426

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

NMRA 335140

Placebo

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

Jacobio Pharmaceuticals Co., Ltd.

Location:

Chicago, Phoenix, Scottsdale, Los Angelesshow 11 more

Code:

NCT04720976

Conditions

Solid Tumor

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

JAB-3312

Binimetinib

Pembrolizumab

Sotorasib

Osimertinib

e.g. Respiratory Diseases

Chicago•Healthy volunteers: No

Filter results

Results: 2,251

Longitudinal Study of the Porphyrias

Recruiting

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Chicago, Birmingham, Los Angeles, San Franciscoshow 11 more

Code:

NCT01561157

Conditions

Acute Porphyrias

Cutaneous Porphyrias

Eligibility Criteria

Sex: All

Age: 1+

Healthy Volunteers: Not accepted

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

Recruiting

Sponsor:

Northwestern University

Location:

Chicago

Code:

NCT01531257

Conditions

Acute Rejection (AR) of Transplanted Kidney

Chronic Allograft Nephropathy (CAN)

Interstitial Fibrosis (IF)

Tubular Atrophy (TA)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Recruiting

Phase 3

Sponsor:

Dermavant Sciences, Inc.

Location:

Chicago, Rogers, Fountain Valley, Rancho Santa Margaritashow 7 more

Code:

NCT05172726

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

tapinarof cream, 1%

Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder

Recruiting

Phase 3

Sponsor:

Neumora Therapeutics, Inc.

Location:

Chicago, Warrenville, Evanston, Huntsvilleshow 55 more

Code:

NCT06029426

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

NMRA 335140

Placebo

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

Sponsor:

Jacobio Pharmaceuticals Co., Ltd.

Location:

Chicago, Phoenix, Scottsdale, Los Angelesshow 11 more

Code:

NCT04720976

Conditions

Solid Tumor

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

JAB-3312

Binimetinib

Pembrolizumab

Sotorasib

Osimertinib